Jadite, seeing that Stephen Carey was part of PAR when they went private for $1.8 billion and was later sold approx. 3 years later to Endo for $8 billion, I am concerned.
Ani shareholders gave up 43% of their company and was originally willing to give up 47% to BPAX share holders for the merger. Original BPAX and now ANP shareholders must be given the chance to benefit from Libigel's success or be given compensation commensurate with Libigel discoveries being public knowledge.
To accept a low ball offer without informing the shareholders, especially if AbbVie or another pharma picks it up and makes billions, places management along with BPAX management and their BODs in a position to be investigated and most likely charged with conspiracy to defraud investors. Especially when I help lay out the case for them. Remember that the sale doesn't even have to be successful to support conspiracy charges. That is a big gamble on their part.
I believe Przybyl is one of the good ones, he always credits his staff, is prudent in asset acquisitions. I believe he and the company will take care of their shareholders, I don't think they are so wreckless as to even try low-ball shareholders.
If it is AbbVie buying us out, the CV announcements should come out at the same time as the buyout is announced. That way AbbVie can justify to their shareholders why they are paying so much.
JMHO
News 
Market Data 
Discover 
AI
